Some estimates
If Envoy’s Acclaim gets full FDA approval and achieves traction, a realistic multi-year steady-state revenue target is in the low hundreds of millions (USD) if it captures a mid single-digit market share; tens of millions is more realistic in the first 1–3 years under conservative uptake assumptions. All of this depends heavily on reimbursement, surgeon adoption, and clinical outcomes compared with entrenched competitors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jimmyyyyyyy OP : this is a big fundamental shift…
105671636_HNM(INT) : sound like can invest hor? master what is the TP BUY?
105519319 MYname is Jimmyyyyyyy OP : inzzzzzs
Jimmyyyyyyy OP 105519319 MYname is : we fall to hell tgt
Jimmyyyyyyy OP 105671636_HNM(INT) : from how i see it is it is more than tradeable, investable as well
105519319 MYname is Jimmyyyyyyy OP : lets go master @Jimmyyyyyyy fall at 3!!!!![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
105671636_HNM(INT) Jimmyyyyyyy OP : noted. may i know what is your tp sell?
Budgetmania : Good point. investable for long term.
Jimmyyyyyyy OP 105671636_HNM(INT) : lets see if 5 is achievable first